跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

SML0572

Sigma-Aldrich

Valspodar

≥98% (HPLC)

别名:

6-[(2S,4R,6E)-4-Methyl-2-(methylamino)-3-oxo-6-octenoic acid]cyclosporin D, Amdray, PSC833, [3′-Desoxy-3′-oxo-MeBmt]1-[Val]2-cyclosporin

登录查看公司和协议定价

选择尺寸

5 MG
$212.00
25 MG
$839.00

$212.00

请联系客服了解存货情况
获取大包装报价
所有图片(1)

选择尺寸

变更视图
5 MG
$212.00
25 MG
$839.00

About This Item

经验公式（希尔记法）:
C63H111N11O12
CAS号:
121584-18-7
分子量:
1214.62
MDL编号:
MFCD00907207
UNSPSC代码:
12161501
NACRES:
NA.77

$212.00

请联系客服了解存货情况
获取大包装报价

方案

≥98% (HPLC)

表单

powder

储存条件

desiccated

颜色

white to beige

运输

wet ice

储存温度

−20°C

SMILES字符串

N1([C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C1=O)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)C(C)C)C(=O)[C@@H](C\C=C\C)C)C)C(C)C)C

InChI

1S/C63H111N11O12/c1-26-27-28-41(16)53(76)52-57(80)67-49(38(10)11)61(84)68(19)33-48(75)69(20)44(29-34(2)3)56(79)66-50(39(12)13)62(85)70(21)45(30-35(4)5)55(78)64-42(17)54(77)65-43(18)58(81)71(22)46(31-36(6)7)59(82)72(23)47(32-37(8)9)60(83)73(24)51(40(14)15)63(86)74(52)25/h26-27,34-47,49-52H,28-33H2,1-25H3,(H,64,78)(H,65,77)(H,66,79)(H,67,80)/b27-26+/t41-,42+,43-,44+,45+,46+,47+,49+,50+,51+,52+/m1/s1

InChI key

YJDYDFNKCBANTM-QCWCSKBGSA-N

正在寻找类似产品? 访问 产品对比指南

应用

Valspodar/ PSC-833 has been used as a ABCB1 (P-glycoprotein) inhibitor.[1]

生化/生理作用

Valspodar is a nonimmunosuppressive cyclosporin analog and potent P-glycoprotein (MDR1) inhibitor.
Valspodar is a nonimmunosuppressive cyclosporin analog and potent P-glycoprotein (MDR1) inhibitor. Valspodar reverses multidrug resistance (MDR) by inhibiting cellular drug efflux mediated by P-glycoprotein.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000420220
0000420220
0000269481
0000236125
0000269482

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Ziyad Binkhathlan et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 81(1), 142-148 (2012-03-01)
Co-administration of P-glycoprotein (P-gp) inhibitors such as cyclosporine A (CyA) and its analogue valspodar with doxorubicin (DOX) can result in diminished clearance of DOX, leading to accentuated toxicity. The purpose of this study was to evaluate whether the effect of
Jonathan E Kolitz et al.
Blood, 116(9), 1413-1421 (2010-06-05)
Cancer and Leukemia Group B 19808 (CALGB 19808) is the only randomized trial of a second-generation P-glycoprotein (Pgp) modulator in untreated patients with acute myeloid leukemia (AML) younger than age 60 years. We randomly assigned 302 patients to receive induction
Kohjiro Nagao et al.
Biochimica et biophysica acta, 1831(2), 398-406 (2012-11-17)
ATP-binding cassette protein A1 (ABCA1) plays a key role in generating high-density lipoprotein (HDL). However, the detailed mechanism of HDL formation remains unclear; in order to reveal it, chemicals that specifically block each step of HDL formation would be useful.
Ziyad Binkhathlan et al.
Current drug delivery, 9(2), 164-171 (2012-01-31)
The aim of this study was to characterize the nanostructures formed from assembly of poly(ethylene oxide)-bpoly( α-benzyl carboxylate ε-caprolactone) (PEO-b-PBCL) in water, determine the effect of weight fraction of the hydrophilic block( fEO) on their morphology, and to investigate their
Liang Jin et al.
Antimicrobial agents and chemotherapy, 55(2), 502-507 (2010-12-01)
The aim of this study was to investigate the factors limiting the blood-brain barrier (BBB) transport of colistin in healthy mice and to assess the impact of systemic inflammation on the transport of this antibiotic across the BBB. Colistin sulfate
查看所有相关文献

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门